Ernexa Therapeutics Inc. (ERNA) Free cash flow 2016–2025
Ernexa Therapeutics Inc. (ERNA) annual free cash flow history — operating cash flow minus capital expenditures, per SEC filings.
-$7.1MFY2025 · since FY2016: -$404,000 → -$7.1M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -$7.1M | +56.5% |
| FY2024 | -$16.2M | +20.7% |
| FY2023 | -$20.4M | +4.0% |
| FY2022 | -$21.3M | +10.0% |
| FY2021 | -$23.6M | -190.4% |
| FY2020 | -$8.1M | -411.2% |
| FY2019 | $2.6M | +264.9% |
| FY2018 | $717,000 | +500.6% |
| FY2017 | -$179,000 | +55.7% |
| FY2016 | -$404,000 | — |
Free cash flow = reported operating cash flow − reported capital expenditures for the same fiscal year.
Source: SEC XBRL filings · For reference only · Not investment advice
More ERNA financial trends
ERNA RevenueERNA Net incomeERNA Net marginERNA Gross profitERNA Gross marginERNA Operating incomeERNA Operating marginERNA Operating cash flowERNA Capital expendituresERNA Return on equityERNA Stock buybacksERNA Dividends paidERNA Total assetsERNA Total liabilitiesERNA Shareholders’ equityERNA overview →